CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

Clinical trial NCT04021082 · WITHDRAWN

Trial details

NCT number: NCT04021082
Sponsor: Portola Pharmaceuticals
Status: WITHDRAWN
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Peripheral T-Cell Lymphoma (PTCL NOS)Nodal Lymphomas of T Follicular Helper (TFH)Follicular T-cell Lymphoma (FTCL)AITL ALCL HSTCL EATL I,II MEITL, EATL Type II Nasal Lymphoma

Start date: 2019-11-15
Primary completion: 2022-12-31
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.